ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience(TM) Line of Dietary Supplements
IRVINE, Calif., May 17, 2012 /PRNewswire/ — ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today that customer demand and unit sales of its recently launched BluScience(TM) line of dietary supplements have exceeded the Company’s initial forecast and expectations during the first quarter ended March 31, 2012.
The nationwide launch of BluScience(TM) in retail outlets began in earnest in early 2012 whereby BluScience(TM) became available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S.
In the first quarter of 2012, the initial launch achieved sales of more than 125,000 units of BluScience(TM), more than 50 percent higher than the Company’s initial forecast. Sales deductions for promotions and discounts related to the sale of BluScience(TM) product totaled $2,249,168 in the first quarter, resulting in net sales of BluScience(TM) products of $69,742. Higher than expected consumer demand for the BluScience(TM) line resulted in higher than expected promotional expenses.
As planned, promotional activities, discounted pricing and media programs were used to generate interest, and played a key role in the launch and initial consumer awareness of the product line.
Frank Jaksch, Co-Founder and CSO of ChromaDex® commented, “ChromaDex® made a strategic decision to significantly invest in our patented and proprietary pTeroPure® by creating and launching the BluScience(TM) product line as well as financing the first human clinical study of pTeroPure®. The results will provide an important independent clinical assessment of what we believe is an enormous opportunity with this product.”
ChromaDex® announced in December 2011 the successful completion of enrollment in the first human clinical study of pTeroPure®. The randomized, double-blind placebo-controlled study evaluated pTeroPure® effects on blood pressure, total triglycerides, cholesterol, as well as improve markers for oxidative stress in patients with dyslipidemia-meeting inclusion criteria. Investigators are also evaluating the safety of pTeroPure® in these patients and other ends points, such as weight loss.
The BluScience(TM) line is currently comprised of:
- EternalBlu – supports cellular health and has anti-aging properties
- HeartBlu – helps maintain healthy cholesterol levels and supports cardiovascular health
- MemoryBlu – supports concentration, memory and cognitive function
- TrimBlu – helps control appetite and supports healthy metabolism
- Blu2Go – provides a sustained energy boost and supports focus & mental clarity
The novel ingredient in Bl?Science(TM) is ChromaDex®‘s proprietary, patented pterostilbene, branded as pTeroPure®, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.
pTeroPure® is a proprietary, nature-identical formulation of the compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (phytochemicals with antioxidant activities that help fight free radicals), allowing more time for its antioxidant activities to act. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience(TM) capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.
ChromaDex®, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights. The company recently launched its BluScience(TM) line of dietary supplements, now available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in North America. BluScience(TM) is also available at a prominent online retailer, as well as a national health and nutrition products retailer. Capitalizing on the diverse potential applications of the product, ChromaDex® is also investigating pTeroPure® for the skincare and pharmaceutical markets, among others. pTeroPure® is currently being studied in a human clinical trial at the University of Mississippi. For more information about pTeroPure® visit www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies’ filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex® Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
ChromaDex® / BluScience(TM) Contact:
Laura Carney, Executive Assistant